# Sanofi clinical trials: 1,560 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 1,560 trials with Sanofi as lead sponsor, 85 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Sanofi: 1,560 rows for $78, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 5 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/sanofi

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 1,560
- Recruiting or not yet: 85
- Read on: November 19, 2026

## Trials

The 25 newest of 1,560, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07944885 | First-in-human Study of SAR448632 in Healthy Adult Participants | Sanofi | Phase 1 | Not yet recruiting | Healthy Volunteer | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07944885) |
| November 17, 2026 | NCT07941622 | Study of Hexaxim Compared With Pentaxim Administered With a Monovalent Hepatitis B Vaccine in Healthy Chinese Infants. | Sanofi | Phase 3 | Not yet recruiting | Haemophilus Influenzae Type b Immunisation, Hepatitis B Immunisation, Polio Immunization, Pertussis Immunisation... | 720 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07941622) |
| November 12, 2026 | NCT07930624 | A Study to Investigate Long-term Safety and Tolerability of Frexalimab in Participants With Multiple Sclerosis | Sanofi | Phase 3 | Not yet recruiting | Multiple Sclerosis | 2,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07930624) |
| November 10, 2026 | NCT07927140 | The Efficacy and Safety of Venglustat Compared With Cerezyme in Pediatric Participants 2 to 11 Years of Age With Gaucher Disease Type 3... | Sanofi | Phase 3 | Not yet recruiting | Gaucher's Disease Type III | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07927140) |
| November 6, 2026 | NCT07923383 | An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 Substrates | Sanofi | Phase 1 | Not yet recruiting | Ulcerative Colitis, Crohn's Disease | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923383) |
| November 6, 2026 | NCT07923305 | Phase 2 and 3 Placebo Controlled & Long-term Extension Study of Rilzabrutinib in Adults With iCVID to Evaluate Efficacy, Safety, and... | Sanofi | Phase 2/3 | Not yet recruiting | Immunodeficiency Common Variable | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923305) |
| November 5, 2026 | NCT07919899 | Pharmacokinetics, Immunogenicity and Safety of Subcutaneous Dupilumab and Berahyaluronidase Alfa (ALT-B4) Coformulation | Sanofi | Phase 3 | Not yet recruiting | Dermatitis Atopic | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919899) |
| October 30, 2026 | NCT07906132 | A Retrospective Cohort Study Evaluating Major Adverse Cardiovascular Events and Cardiovascular Outcomes in Adults With Atherosclerotic... | Sanofi | Observational | Completed | Atherosclerotic Cardiovascular Disease | 93,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07906132) |
| October 29, 2026 | NCT07905547 | A Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic Dermatitis | Sanofi | Phase 4 | Not yet recruiting | Atopic Dermatitis | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07905547) |
| October 29, 2026 | NCT07905534 | A Retrospective Cohort Study Evaluating Major Adverse Cardiovascular Events and Cardiovascular Outcomes in Adults With Atherosclerotic... | Sanofi | Observational | Active not recruiting | Atherosclerotic Cardiovascular Disease | 18,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07905534) |
| October 29, 2026 | NCT07905508 | A Retrospective Cohort Study Evaluating Major Adverse Cardiovascular Events and Cardiovascular Outcomes in Adults With Atherosclerotic... | Sanofi | Observational | Completed | Atherosclerotic Cardiovascular Disease | 180,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07905508) |
| October 27, 2026 | NCT07898371 | A Study to Describe Multiple Sclerosis Patients Treated With Tolebrutinib as Per Label in a Real-world Setting | Sanofi | Observational | Recruiting | Multiple Sclerosis | 3,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07898371) |
| October 26, 2026 | NCT07895381 | A Study to Describe Patient REal-world FitusiRan ExpeRience | Sanofi | Observational | Not yet recruiting | Hemophilia A or B | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07895381) |
| October 22, 2026 | NCT07890454 | Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult... | Sanofi | Phase 3 | Recruiting | Immunization, Healthy Volunteers, COVID-19 Immunization, Influenza Immunization | 6,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890454) |
| October 6, 2026 | NCT07861542 | Study of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at Increased Risk of Severe COVID-19 | Sanofi | Phase 4 | Active not recruiting | COVID-19 | 669 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07861542) |
| October 2, 2026 | NCT07855250 | An Open-label DDI Study to Investigate the Effect of Rilzabrutinib on P-gp, BCRP, OATP1B1 and OATP1B3 Inhibition | Sanofi | Phase 1 | Active not recruiting | Healthy Volunteer | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07855250) |
| October 1, 2026 | NCT07853131 | Study to Assess the Plasma Concentration of Rilzabrutinib Given as a Tablet to Adult Participants With Severe Renal Impairment Compared to... | Sanofi | Phase 1 | Recruiting | Renal Impairment, Healthy Volunteers | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07853131) |
| September 10, 2026 | NCT07812116 | A Study to Investigate Efficacy and Safety of Duvakitug in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | Sanofi | Phase 2 | Recruiting | Hidradenitis | 156 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07812116) |
| September 9, 2026 | NCT07810010 | Phase 2b Study of a Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Protein Vaccine Candidate in Adults 60 Years of Age... | Sanofi | Phase 2 | Recruiting | Respiratory Syncytial Virus, Human Metapneumovirus, Healthy Volunteers | 8,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07810010) |
| August 28, 2026 | NCT07793409 | A Study to Evaluate the Long-term Safety and Efficacy of Lunsekimig in Adult Participants With Chronic Obstructive Pulmonary Disease (COPD) | Sanofi | Phase 3 | Enrolling by invitation | Chronic Obstructive Pulmonary Disease | 1,508 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07793409) |
| August 21, 2026 | NCT07779408 | Study to Assess Safety and Immunogenicity of an Egg-based H5N8 Influenza Vaccine at Multiple Dose Levels Adjuvanted With Matrix-M in... | Sanofi | Phase 1/2 | Recruiting | Healthy Volunteers, Influenza | 640 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07779408) |
| August 18, 2026 | NCT07771439 | A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older... | Sanofi | Phase 3 | Recruiting | Chronic Graft Versus Host Disease | 356 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07771439) |
| August 11, 2026 | NCT07756957 | Safety of the Acne mRNA Vaccine in Adolescents 12 to 17 Years of Age With Moderate to Severe Acne | Sanofi | Phase 1/2 | Recruiting | Acne | 410 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07756957) |
| July 29, 2026 | NCT07734753 | Impact of Alirocumab on Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease But Without Prior Ischemic Events | Sanofi | Observational | Completed | Atherosclerotic Cardiovascular Disease Without Prior Ischemic Events | 4,006 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07734753) |
| July 29, 2026 | NCT07734649 | Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older | Sanofi | Phase 1/2 | Recruiting | Respiratory Syncytial Virus Immunization, Human Metapneumovirus Immunization, Healthy Volunteers | 2,400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07734649) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 234 |
| Phase 1/2 | 49 |
| Phase 2 | 304 |
| Phase 2/3 | 16 |
| Phase 3 | 560 |
| Phase 4 | 282 |
| Not applicable | 10 |
| Observational | 105 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 1,205 |
| Terminated | 179 |
| Recruiting | 73 |
| Active not recruiting | 68 |
| Withdrawn | 13 |
| Not yet recruiting | 12 |
| Enrolling by invitation | 5 |
| Available | 1 |
| Approved for marketing | 1 |
| No longer available | 1 |
| Suspended | 1 |
| Unknown | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Diabetes Mellitus, Type 2 | 184 |
| Diabetes Mellitus, Type 1 | 61 |
| Neoplasms | 60 |
| Dermatitis, Atopic | 38 |
| Hypercholesterolemia | 37 |
| Asthma | 37 |
| Diabetes Mellitus | 33 |
| Breast Neoplasms | 32 |
| Hypertension | 29 |
| Multiple Sclerosis | 29 |
| Arthritis, Rheumatoid | 27 |
| Prostatic Neoplasms | 25 |
| Atrial Fibrillation | 23 |
| Depression | 22 |
| Influenza, Human | 22 |
| Obesity | 21 |
| Whooping Cough | 20 |
| Neoplasm Metastasis | 20 |
| Carcinoma, Non-Small-Cell Lung | 19 |
| Multiple Myeloma | 19 |
| Diphtheria | 18 |
| Tetanus | 18 |
| Sleep Initiation and Maintenance Disorders | 18 |
| Poliomyelitis | 15 |
| Pulmonary Disease, Chronic Obstructive | 15 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Otolaryngology practices in the United States](https://specstream.ai/data/businesses/otolaryngology-practices/united-states)
- [Gerontology practices in the United States](https://specstream.ai/data/businesses/gerontology-practices/united-states)
- [Carpenters in the United States](https://specstream.ai/data/businesses/carpenters/united-states)
- [Vegan restaurants in the United States](https://specstream.ai/data/businesses/vegan-restaurants/united-states)
- [Peruvian restaurants in the United States](https://specstream.ai/data/businesses/peruvian-restaurants/united-states)
- [Honduran restaurants in the United States](https://specstream.ai/data/businesses/honduran-restaurants/united-states)
